Introduction

Cutaneous manifestations of spondyloarthritis

“Nature has neither core nor skin: she’s both at once outside and in.”

Pondyloarthritis (SpA) is a family of inflammatory rheumatic diseases, sharing a genetic predisposition involving multiple genes interacting with environmental factors. Collectively, SpA has a global prevalence of 1.9%, being rare in Southern African populations where the frequency of HLA B27 is <1%. Under this umbrella, SpA includes axial spondyloarthritis (radiographic and non radiographic), psoriatic arthritis, SpA associated with inflammatory bowel disease (IBD), reactive arthritis and undifferentiated SpA, with characteristic cutaneous manifestations which may precede joint involvement, infer loss of efficacy of current therapies, or be treatment induced.

Comorbidities in spondyloarthritis (SpA)

SpA refers to a constellation of inflammatory diseases that affect axial, peripheral joints and etheses with the possible association of extra-articular manifestations (uveitis, inflammatory bowel disease, psoriasis).

Ophthalmic manifestations of AS

Uveitis may occur with a variety of systemic inflammatory diseases. However, by far the most common association is between inflammation of the uvea and the joints. In adults, the so-called sero-negative spondyloarthropathies, which occur in the context of HLA-B27 and include ankylosing spondylitis and reactive arthritis, may be associated with an acute onset of uveitis. Psoriatic arthritis and inflammatory bowel disease may also cause uveitis. Acute onset anterior uveitis is the most common form of uveitis and occurs in 4 per 1000 of the population over a lifetime.

Navigating access of biologics for your patient and medical schemes

Biological medicines, as well as biosimilars, are invaluable tools in the arsenal of any medical practitioner treating patients with both prescribed minimum benefit (PMB) and non-PMB conditions. Conditions such as ankylosing spondylitis and psoriatic arthritis are not PMBs, but there are still legislated protections for patients with these conditions.

Accreditation

Health Professions Council of South Africa

MDB015/961/06/2022

2 Ethics

Certification

Attempts allowed: 2

70% pass rate

 




Enquire Now

Spondylo Matters - Vol 5 No 1 - 2022

2.0 CPD Points